Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Hamed RCTtocilizumab standard of careCOVID-19 severe or criticallyhigh
26/23 inconclusive
  • inconclusive 83 % increase in deaths (PE) but with a low degree of certainty due to high risk of bias
  • inconclusive 2.2-fold increase in ICU admission (PE) but with a low degree of certainty due to high risk of bias
REMAP-CAP (tocilizumab)
  NCT02735707		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif
  • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
  • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
REMAP-CAP sarilumab
  NCT02735707		 RCTsarilumabstandard of careCOVID-19 severe or criticallyhigh
48/402 conclusif
  • demonstrated 76 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
  • suggested 86 % increase in clinical improvement (14-day) but with a low degree of certainty due to high risk of bias
Rosas (REMDACTA)
  NCT04409262		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive
  • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
Talaschian
  IRCT20081027001411N4		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
    Veiga
          NCT04403685    		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
    		65/64 safety concern
    • safety concern with 1.7-fold increase in deaths,death D28 (not statistically significant)
    • inconclusive 54 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    CORIMUNO-TOCI-1 (Group 1)
          NCT04331808    		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
    		64/67 inconclusive
      CORIMUNO-TOCI-ICU (Group 2)
              NCT04331808      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
      		49/43 inconclusive
        COVACTA (Rosas)
                  NCT04320615        		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
        		301/151 suggested
        • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        NCT04377750 (HMO-0224-20) unpublished
                  NCT04377750        		 RCTtocilizumab placeboCOVID-19 severe or criticallyhigh
        		37/17 inconclusive
          Andrew OBStocilizumab controlCOVID-19 severe or criticallyNA
          		198/413 inconclusive
            ARI-RAF (Della-Torre) OBSsarilumabcontrolCOVID-19 severe or criticallyNA
            		28/28 inconclusive
              Biran OBStocilizumab controlCOVID-19 severe or criticallyserious
              		210/420 suggested
              • suggested 36 % decrease in deaths but with a low degree of certainty due to high risk of bias
              Mathilde OBStocilizumab controlCOVID-19 severe or criticallycritical
              		30/29 suggested
              • suggested 75 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
              Rojas-Marte OBStocilizumab controlCOVID-19 severe or criticallycritical
              		96/97 inconclusive
                Somers OBStocilizumab controlCOVID-19 severe or criticallycritical
                		78/76 safety concern
                • suggested 45 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                • statistically significant 2.3-fold increase in superinfection but with a very low degree of certainty due to critical risk of bias
                TOCI-RAF Study Group (Campochiaro) OBStocilizumab controlCOVID-19 severe or criticallyNA
                		32/33 inconclusive

                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                   

                  - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons